Valuation: Mylan Inc

Market Cap 18.95B 16.62B 15.39B 14.16B 26.79B 1,813B 27.31B 183B 71.95B 891B 71.15B 69.59B 3,076B P/E 2026 *
69.8x
P/E 2027 * 25.8x
Enterprise Value 31.13B 27.31B 25.29B 23.27B 44.02B 2,980B 44.87B 301B 118B 1,463B 117B 114B 5,054B EV / Sales 2026 *
2.11x
EV / Sales 2027 * 1.99x
Free-Float
92.23%
Yield 2026 *
3.13%
Yield 2027 * 3.21%
Manager TitleAgeSince
Chief Executive Officer 63 01/04/2023
Director of Finance/CFO 59 08/05/2026
Chief Tech/Sci/R&D Officer - 15/12/2023
Director TitleAgeSince
Director/Board Member 78 16/11/2020
Director/Board Member 78 16/11/2020
Director/Board Member 62 16/11/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.56%-1.52%+47.86%+171.88% 1,060B
+0.31%-0.60%+64.37%+62.31% 619B
-0.03%-2.65%+29.49%+85.64% 438B
-1.75%-0.33%+28.33%+23.58% 333B
+0.24%-0.42%+29.19%+47.26% 282B
-1.75%-10.57%+18.27%+22.07% 267B
+0.67%+1.03%-26.81%-37.96% 218B
-0.81%-1.63%+21.35%+58.33% 196B
+1.21%+1.38%+17.23%+71.29% 161B
Average -0.51%-3.33%+25.47%+56.05% 397.1B
Weighted average by Cap. -0.58%-3.10%+35.57%+83.94%

Financials

2026 *2027 *
Net sales 14.77B 12.96B 12B 11.04B 20.89B 1,414B 21.29B 143B 56.1B 694B 55.48B 54.27B 2,398B 15.04B 13.19B 12.22B 11.24B 21.26B 1,439B 21.67B 146B 57.1B 707B 56.47B 55.23B 2,441B
Net income 13M 11.4M 10.56M 9.72M 18.38M 1.24B 18.73M 126M 49.36M 611M 48.81M 47.74M 2.11B 498M 436M 404M 372M 703M 47.62B 717M 4.82B 1.89B 23.39B 1.87B 1.83B 80.76B
Net Debt 12.19B 10.69B 9.9B 9.11B 17.23B 1,166B 17.56B 118B 46.28B 573B 45.76B 44.76B 1,978B 11.03B 9.67B 8.96B 8.24B 15.59B 1,056B 15.9B 107B 41.89B 518B 41.42B 40.52B 1,790B
Logo Mylan Inc
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-